Kinnov Therapeutics

Kinnov Therapeutics

First-in-class therapy for a worldwide market

Menu

  • Company
  • Alcohol addiction
  • R&D / Pipeline
  • Product KT-110
  • Partners / Investors
  • Business strategy
  • News
  • Contact us

European and US addiction KOLs provide their insight on AUD and KT-110 (video)

In a 11-min video, five experts in addiction explain why KT-110 is a game changer and why it is a hope for millions of AUD patients.   Henri-Jean Aubin is Professor of Psychiatry and Addictology at Hôpital Pitié-Salpétrière in Paris,

Lucas Biela October 30, 2024October 30, 2024 news Read more

Kinnov Therapeutics was present at the 37th ECNP Congress

Kinnov Therapeutics was present at the 37th ECNP Congress

Kinnov Therapeutics was present at the 37th ECNP congress https://www.ecnp.eu/congress2024/ECNPcongress, in Milan 21-24 Sep, 2024. Within the scope of ECNP’s New Medications Symposium, Prof Henri-Jean Aubin and Julien Guiraud were invited to present results of phase 2 clinical trials. The

Lucas Biela October 30, 2024October 30, 2024 news Read more

Co-funded by the horizon 2020 programme of the European Union

About us

Kinnov Therapeutics is dedicated to the R&D of innovative therapies against addiction. Supported by experienced scientists in the drug discovery and development, we have identified the key receptors of addiction. KT-110, our first-in-class lead composition, has been tested in phase 2 clinical trial for alcohol addiction.

Contact Us

Kinnov-Therapeutics

3, allée du titane
45100 Orléans, France


View Larger Map

Pages

  • Addictions: a major Public Health threat
  • Alcohol addiction
  • Business strategy
  • Company
  • Contact us
  • Home
  • Partners / Investors
  • Preclinical trials
  • Product KT-110
  • R&D / Pipeline

Copyright 2020 - Kinnov Therapeutics